Innova Captab about to file Rs 900-crore IPO with SEBI
Drugmaker Innova Captab will soon file a draft red herring prospectus (DRHP) with request controller Sebi for a ₹ 900- crore original public immolation (IPO), people in the know said. The Mumbai- grounded company is engaged in contract development and manufacturing of general phrasings. It’s looking to raise ₹ 700- 900 crore, according to the people cited before, and it’ll have a fresh issue and offer for trade element.
The company has appointed JM Financial NSE-0.60 and ICICI Securities NSE0.54 as bankers to the issue, they said. Innova didn’t reply to ET’s request seeking a comment.
The company has considerable presence in the acute and habitual rectifiers’ member, especially in cardio metabolic, respiratory, neuroscience, contagious conditions and vaccines. It’s present across the entire pharma value chain that includes exploration and development, manufacturing, medicine distribution, marketing and exports. The drugmaker has two WHO GMP certified manufacturing installations in Baddi and also has a CSIR approved R&D installation.
Innova was innovated as a cooperation establishment in 2005 by Gian Prakash Aggarwal, Manoj Kumar Lohariwala and Vinay Kumar Lohariwala. Later, in March 2021, it took over the cooperation establishment on a depression trade base which was funded through term loans. A CARE Conditions report in April 2022 on Innova indicated a modification in its standing from BBB to A- for its long- term bank installations, and A2 from A2 for its short- term installations. The long- term debt to equity rate bettered from0.16 X to0.08 X as on March 31, 2021.
Innova Captab Limited
Innova Captab Limited is an unlisted public company incorporated on 03 January, 2005. It is classified as a public limited company and is located in Mumbai City, Maharashtra. Its authorized share capital is INR 64.00 cr and the total paid-up capital is INR 48.00 cr.
Innova Captab Limited’s operating revenues range is INR 100 cr – 500 cr for the financial year ending on 31 March, 2021. It’s EBITDA has increased by 6.98 % over the previous year. At the same time, its book net worth has increased by 31.23 %. Other performance and liquidity ratios are available here.
The Company manufactures tablets, capsules, dry powder injections and antibiotic syrups for various pharmaceutical companies on contract basis.
Products & Services:
Antihyperuricemia, Antigout, Antimalarial, Antiobesity, Antioxidant & Vitamins, Antispasmodic, Anxiolytic, Anticonvulsant & Antipsychotic, Bladder & Prostate Disorder, Cardiovascular.
The current status of Innova Captab Limited is – Active.
The last reported AGM (Annual General Meeting) of Innova Captab Limited, per our records, was held on 30 November, 2021. Also, as per our records, its last balance sheet was prepared for the period ending on 31 March, 2021.
Innova Captab Limited has eight directors – Manoj Kumar Lohariwala, Vinay Kumar Lohariwala, and others. The Corporate Identification Number (CIN) of Innova Captab Limited is U24246MH2005PLC150371. The registered office of Innova Captab Limited is at Office No. 606, Ratan Galaxie-6th Floor, J.N. Road, Plot No. 1, Mulund (W), Mumbai, Mumbai City, and Maharashtra.
Buy Unlisted Share – Click Here